SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-17-345459
Filing Date
2017-11-16
Accepted
2017-11-16 16:02:03
Documents
9
Period of Report
2017-11-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d493949d8k.htm 8-K 22318
2 EX-1.1 d493949dex11.htm EX-1.1 233182
3 EX-4.1 d493949dex41.htm EX-4.1 57706
4 EX-5.1 d493949dex51.htm EX-5.1 12758
5 EX-99.1 d493949dex991.htm EX-99.1 7798
6 EX-99.2 d493949dex992.htm EX-99.2 9325
7 GRAPHIC g493949g1116063021647.jpg GRAPHIC 4945
8 GRAPHIC g493949g1116122815715.jpg GRAPHIC 2234
9 GRAPHIC g493949g1116123640773.jpg GRAPHIC 4945
  Complete submission text file 0001193125-17-345459.txt   361389
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 171208035
SIC: 2834 Pharmaceutical Preparations